Investigating the clinical characteristics of SF3B1-mutated myelodysplastic syndrome with excess blasts (MDS-EB), along with assessing the correlation between SF3B1 mutation status and treatment effectiveness and prognostic implications for MDS-EB patients. A retrospective case series study design was employed. In the First Affiliated Hospital of Zhengzhou University, clinical data were examined for 266 patients with MDS-EB, who were diagnosed between April 2016 and November 2021. Blood routine counts, mutated genes, overall response rate (ORR), overall survival (OS), progression-free survival (PFS), and leukemia-free survival (LFS) were factors included in the observed indicators. Survival curves were illustrated using the Kaplan-Meier approach. Employing the Log-rank test for survival comparisons across groups, alongside a Cox proportional hazards regression model for prognostic evaluation. For the 266 individuals diagnosed with MDS-EB, 166 patients (62.4%) identified as male, with a median age of 57 years and an age range of 17-81 years. In addition, the SF3B1-mutated group contained 26 patients, and the SF3B1 wild-type group included 240 patients. Patients harboring the SF3B1 mutation exhibited a higher median age (65 years, IQR 51-69) compared to the control group (56 years, IQR 46-66), a statistically significant difference (P=0.0033). White blood cell (WBC) counts were significantly higher in the SF3B1-mutated group (308 x 10^9/L, IQR 235-478) compared to the control group (213 x 10^9/L, IQR 140-377). The same pattern was observed for platelet counts (PLT), with the mutated group exhibiting significantly higher values (1225 x 10^9/L, IQR 505-2150) compared to the control group (490 x 10^9/L, IQR 243-1008). Absolute neutrophil counts (ANC) were also significantly higher in the SF3B1-mutated group (183 x 10^9/L, IQR 101-288) than in the control group (80 x 10^9/L, IQR 41-199). Furthermore, the incidence of DNMT3A mutations was significantly higher in the SF3B1-mutated group (231%, 6 of 26 cases) compared to the control group (67%, 16 of 240 cases). (All P-values < 0.05). Similar results for ORR were seen in both groups after completing 2 and 4 cycles of therapy (P=0.0348, P=1.000). Lastly, the LFS (P=0218), PFS (P=0179), and OS (P=0188) showcased a remarkable resemblance across the analyzed cohorts. The results of the univariate Cox analysis indicated that the presence of SF3B1 mutations did not impact the prognosis for MDS-EB patients, as shown by the overall survival (OS) p-value of 0.193 and the progression-free survival (PFS) p-value of 0.184. SF3B1-mutated patients presented with an advanced average age and elevated counts of white blood cells, platelets, and absolute neutrophils. The SF3B1 mutation commonly occurred alongside a DNMT3A mutation. The model's findings indicated no notable difference in efficacy or survival for MDS-EB cases with or without SF3B1 mutations.Evaluating the surgical procedure's impact and anticipated prognosis for patients with newly diagnosed multiple myeloma (NDMM) experiencing bone complications. Between January 1, 2003, and December 31, 2021, a retrospective cohort study at Peking Union Medical College Hospital gathered clinical data from patients with NDMM who had undergone surgery due to spinal cord compression or pathological long bone fractures. Subjects with the same degree of bone disease who had not received biopsy or vertebroplasty/kyphoplasty were selected as controls, while individuals who had undergone these procedures were excluded from the study. Progression-free survival (PFS), overall survival (OS), and visual analogue scale (VAS) and physical status (ECOG) scores were used to determine correlations and differences. The statistical analysis process involved the use of the 2-test, t-test, and Kaplan-Meier techniques. Baseline data, including sex, age, paraprotein type, ISS, lytic lesion count, cytogenetic abnormalities, initial treatment, and ASCT proportion, were analyzed for the surgical group (n=40, 43 interventions) versus the non-surgical group (n=80). All comparisons revealed p-values exceeding 0.005. A statistically significant difference was observed in serum M protein levels between the two groups, with the surgical group demonstrating significantly lower levels (21951644 g/L) compared to the non-surgical group (36182085 g/L), as evidenced by a P-value of 0.0005. The surgical procedure revealed lesions in the axial skeleton (791%, 34 of 43) or the extremities (209%, 9 of 43). Substantial improvement in VAS and ECOG scores occurred after surgery, with VAS scores increasing from 230080 to 660150, indicating statistical significance (P<0.005). Multivariate Cox analysis showed that ISS and ASCT were independent prognostic factors for overall survival (OS). The hazard ratio for ISS was 0.42 (95% CI 0.19-0.93, P=0.031), and the hazard ratio for ASCT was 0.41 (95% CI 0.18-0.97, P=0.041). However, orthopedic surgery did not significantly impact patient survival (P=0.233). Improvements in quality of life and a reduction in bone-related complications were evident in NDMM patients undergoing orthopedic surgical resection, however, survival outcomes remained unchanged.The health of humanity is compromised by the global public health crisis of HIV infection and the subsequent condition of AIDS. Cardiovascular events are significantly impacted by dyslipidemia, a primary risk factor, while elevated plasma cholesterol levels are strongly correlated with over 50% of coronary heart disease cases. The incidence rate of cardiovascular diseases is more pronounced in HIV/AIDS patients than in the general population. Not only conventional risk factors, but also viral replication and suboptimal therapies increase the incidence of atherosclerotic coronary vascular disease (ASCVD) in HIV/AIDS patients. Consequently, a profound understanding of lipid metabolism and its associated dysregulation patterns, coupled with effective management of conventional ASCVD risk factors, and reinforced lipid-control strategies, are crucial for enhancing long-term prognosis and quality of life in HIV/AIDS patients. There is, to date, no uniform viewpoint on lipid management for HIV/AIDS patients undergoing extended antiretroviral therapy (ART). Leveraging the current state of ART in China and the pioneering findings from fundamental research and clinical trials, we gathered distinguished domestic experts in infectious diseases and cardiovascular diseases to compile this expert consensus on the integrated management of lipids in HIV/AIDS patients in China.To achieve standardization of CT-guided local ablation for primary liver cancer in China, the Society of Tumor Ablation Therapy of the Chinese Anti-Cancer Association, the CSCO Ablation Expert Committee, and the Chinese Medical Doctors' Expert Group developed a consensus on CT-guided percutaneous thermal ablation. This consensus was based on current guidelines and incorporates precision medicine, IGTA, and a multidisciplinary approach. The endeavor aimed to establish consistent and improved clinical procedures for CT-guided thermal ablation in the management of primary liver cancerIn the elderly population, colonic ischemia is a relatively frequent occurrence, yet consistent diagnostic criteria and therapeutic guidelines for this condition remain elusive. A guideline for managing colon ischemia in Chinese seniors was developed by experts convened by the Chinese Society of Gastroenterology's Committee of Geriatric Gastroenterology. This guideline, grounded in clinical practice and recent global developments in the field, was meticulously elaborated. This guideline for managing colonic ischemia lesions in the elderly is designed to create standardization and to enhance clinical outcomes.The chronic administration of glucocorticoids results in GIOP, a skeletal ailment defined by a reduction in bone strength and an elevated risk of bone fracture. GIOP, the most frequent form of secondary osteoporosis, exerts a marked influence on the quality of life of those affected. China's current GIOP rate remains elevated, hampered by insufficient public understanding and a deficiency in preventative and treatment standards. Consequently, the Chinese Rheumatology Association, drawing upon both domestic and international expertise, has formulated this standard. Its purpose is to elevate clinician awareness of prevention and treatment, direct standardized diagnosis and management of the condition, and ultimately enhance the overall prognosis for GIOP patients.Metformin displays a powerful effect in lowering glucose, and its advantages span a variety of areas, exceeding its simple hypoglycemic impact. Its cost-effectiveness is evident when used alongside a range of hypoglycemic pharmaceuticals. Considering the absence of compelling evidence for cardiorenal benefits from glucagon-like peptide-1 receptor agonists (GLP-1RAs) or sodium-glucose co-transporter 2 inhibitors (SGLT2is), metformin remains the primary first-line pharmacological treatment for newly diagnosed type 2 diabetes and a crucial component of combined hypoglycemic drug therapy. Patients taking metformin need not worry about an increased risk of liver or kidney issues; however, those with renal impairment should modify their metformin dosage according to their estimated glomerular filtration rate (eGFR). Furthermore, the skillful application of metformin does not amplify the risk of lactic acidosis. Patients on long-term metformin therapy often experience a decline in vitamin B12 levels, prompting the need for consistent monitoring and vitamin B12 supplementation in those with deficient intake or absorption. Subsequent to the progress made in fundamental and clinical metformin research, the expert group updating the consensus statement has updated the guidelines, referencing the 2018 Expert Consensus on the Clinical Application of Metformin.Chronic inflammatory conditions, encompassing spondyloarthritis (SpA), primarily affect the spine and/or peripheral joints. The varied and incapacitating clinical presentations of SpA have a profound negative impact on patient well-being. etc-1002 Pharmaceutical research has produced novel medications targeting cytokines and pathways unique to SpA's pathogenesis, significantly improving treatment strategies for SpA.